Skip to content

Comparative Ayurvedic Management of Fatty Liver

Comparative Clinical Evaluation of a Polyherbal Formulation and Rohitak Abhya Kwath with Pippali Yavkshara Churna in Yakrutodara (Non Alcoholic Fatty Liver Disease)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044335
Enrollment
40
Registered
2022-07-26
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Sponsors

Patanjali Ayurveda College
Lead Sponsor
Dr Divya Sharma
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients between the age group of 18-65 years will be selected. 2. Patients irrespective of sex, religion, occupation and chronicity will be selected for the study. 3. Both fresh and treated cases will be taken for the study. 4. Patients with higher LFT levels than the upper limit of normal value will be selected. 5. Patients with GRADE 1 & GRADE 2 fatty liver will be selected for the study. 6. Patients with controlled Diabetes Mellitus having GRADE 1 & GRADE 2 fatty liver will be selected for the study.

Exclusion criteria

Exclusion criteria: 1. Patients aged 65 years will be excluded. 2. Pregnant or lactating women will be excluded. 3. Patients who have had Hepatitis B , Hepatitis C or other hepatic viral infection, autoimmune hepatitis and drug induced hepatitis or alcoholic hepatitis will be excluded. 4. Patients with severe complications of cardiovascular, renal or hematopoietic systems and mental diseases will be excluded. 5. Patients will be excluded having decompensated liver disease. 6. Patients with prolonged or a history of ascites, developed hepato-cellular carcinoma, hepatic encephalopathy, variceal bleeding will be excluded. 7. Patients with the history of using IFN or antiviral agents or corticosteroids or immunosuppressive drugs will also be excluded. 8. Patients having GRADE 3 fatty liver disease will be excluded.

Design outcomes

Primary

MeasureTime frame
All investigations like Ultrasonography, LFT especially including SGOT, SGPT & Alkaline Phosphatase levels.Timepoint: Before intervention and follow up at every 1 month.

Secondary

MeasureTime frame
All investigations like Ultrasonography, LFT especially including SGOT, SGPT & Alkaline Phosphatase levels.Timepoint: After intervention at 3 months.

Countries

India

Contacts

Public ContactDr C B Dhanraj

Patanjali Bhartiya Ayurvigyan Evam Anusandhan Sansthan, Haridwar

drcbdhanraj@gmail.com7396174582

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026